Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma

Sorafenib is an oral angiogenetic multikinase inhibitor approved in the treatment of renal and hepatocellular carcinoma. Bleeding and venous thrombotic events have been described with angiogenetic agents but cerebrovascular accidents are rarely reported. We report two cases of patients with hepatoce...

Descripción completa

Detalles Bibliográficos
Autores principales: Saif, Muhammad W., Isufi, Iris, Peccerillo, Jennifer, Syrigos, Kostas N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113260/
https://www.ncbi.nlm.nih.gov/pubmed/21687621
http://dx.doi.org/10.1155/2011/616080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113260/
https://www.ncbi.nlm.nih.gov/pubmed/21687621
http://dx.doi.org/10.1155/2011/616080

Ejemplares similares